BSH 2022 | Mosunetuzumab monotherapy in R/R FL
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, Sutton, UK, shares the results of the dose expansion phase of a study evaluating mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received a median of three lines of prior therapy. The study reported an overall response rate (ORR) of 80%, a complete response (CR) rate of 60%, and a progression-free survival (PFS) of 18 months. The drug appeared to be well tolerated, with low rates of grade 1-2 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honoraria: Abbvie; AstraZeneca; Gilead, Janssen; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kirin
